The administration of drugs to the central nervous system (CNS) is primarily controlled by
the blood-brain barrier (BBB), a structure that prevents the passage of foreign compounds …

The biomolecules in the clinical use being delivered by the conventional mode of delivery
often exhibit poor affinity. So, there is a need for a nanomedicine-based approach that could …

Intranasal administration is a drug delivery approach to provide a non-invasive
pharmacological response in the central nervous system with relatively small peripheral side …

Epilepsy is a chronic neurological disorder affecting 70 million people globally. One of the
fascinating attributes of brain microvasculature is the (BBB), which controls a chain of distinct …

Brain disorders are a prevalent and rapidly growing problem in the medical field as they
adversely affect the quality of life of a human. With an increase in life expectancy, it has been …

Aim The inability of drug molecules to cross the 'Blood-Brain Barrier'restrict the effective
treatment of Alzheimer's disease. Lipid nanocarriers have proven to be a novel paradigm in …

The transport of drugs to the brain becomes a key concern when treating disorders of the
central nervous system. Parkinsonism is one of the major concerns across the world …

One of the most challenging problems of the current treatments of neurodegenerative
diseases is related to the permeation and access of most therapeutic agents to the central …

Background: Besides systemic drug delivery, the intranasal route of administration has
shown potential for direct nose-to-brain drug delivery, which has gained popularity because …

The purpose of this study was to synthesize duloxetine (DLX)-loaded Eudragit-Chitosan
(Eud-CHT) nanoparticles enclosed in an oral gelatin capsule and to evaluate the potential to …